

**AMBER PHARM LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

Amber Pharm Ltd Contents

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

Amber Pharm Ltd
Balance Sheet
As At 31 December 2025

Registered number: 12370121

		2025		2024	
	Notes	£	£	£	£
FIXED ASSETS					
Intangible Assets	4		660,323		801,810
Tangible Assets	5		50,122		42,786
Investments	6		1,966,167		1,966,167
			2,676,612		2,810,763
CURRENT ASSETS					
Stocks	7	183,582		144,032	
Debtors	8	1,204,895		1,585,213	
Cash at bank and in hand		55,697		165,464	
			1,444,174		1,894,709
Creditors: Amounts Falling Due Within One Year	9	(1,312,020)		(1,485,863)	
NET CURRENT ASSETS (LIABILITIES)			132,154		408,846
TOTAL ASSETS LESS CURRENT LIABILITIES			2,808,766		3,219,609
Creditors: Amounts Falling Due After More Than One Year			(2,471,086)		(2,724,908)
NET ASSETS			337,680		494,701
CAPITAL AND RESERVES					
Called up share capital	11		100		100
Profit and Loss Account			337,580		494,601
SHAREHOLDERS' FUNDS			337,680		494,701

Amber Pharm Ltd
Balance Sheet (continued)
As At 31 December 2025

For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Hiren Patel
Director
01/07/2026

Mr Nicky Patel
Director

Mr Baldev Bange
Director

The notes on pages 3 to 6 form part of these financial statements.

Amber Pharm Ltd
Notes to the Financial Statements
For The Year Ended 31 December 2025

1. General Information

Amber Pharm Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12370121. The registered office is St. James House, 65 Mere Green Road, Sutton Coldfield, West Midlands, B75 5BY.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 10 years.

2.4. Intangible Fixed Assets and Amortisation - Other Intangible

Other intangible assets are measured at cost less accumulated amortisation. They are amortised to profit and loss account over their estimated economic life of 5 years.

2.5. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Motor Vehicles	10% reducing balance
Fixtures & Fittings	20% straight line
Computer Equipment	25% straight line

2.6. Leasing and Hire Purchase Contracts

Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the profit and loss account as incurred.

2.7. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

2.8. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 26 (2024: 25)

4. Intangible Assets

	Goodwill	Other	Total
	£	£	£
Cost			
As at 1 January 2025	1,405,000	4,936	1,409,936
As at 31 December 2025	1,405,000	4,936	1,409,936
Amortisation			
As at 1 January 2025	606,161	1,965	608,126
Provided during the period	140,500	987	141,487
As at 31 December 2025	746,661	2,952	749,613
Net Book Value			
As at 31 December 2025	658,339	1,984	660,323
As at 1 January 2025	798,839	2,971	801,810

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

5. Tangible Assets

	Motor Vehicles	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£
Cost				
As at 1 January 2025	57,023	2,857	17,687	77,567
Additions	10,000	-	3,668	13,668
Disposals	-	-	(14,219)	(14,219)
As at 31 December 2025	67,023	2,857	7,136	77,016
Depreciation				
As at 1 January 2025	17,232	1,642	15,907	34,781
Provided during the period	4,591	572	1,144	6,307
Disposals	-	-	(14,194)	(14,194)
As at 31 December 2025	21,823	2,214	2,857	26,894
Net Book Value				
As at 31 December 2025	45,200	643	4,279	50,122
As at 1 January 2025	39,791	1,215	1,780	42,786

6. Investments

	Subsidiaries
	£
Cost or Valuation	
As at 1 January 2025	3,437,318
As at 31 December 2025	3,437,318
Provision	
As at 1 January 2025	1,471,151
As at 31 December 2025	1,471,151
Net Book Value	
As at 31 December 2025	1,966,167
As at 1 January 2025	1,966,167

7. Stocks

	2025	2024
	£	£
Materials	183,582	144,032

Amber Pharm Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025

8. Debtors

	2025	2024
	£	£
Due within one year		
Trade debtors	275,429	4,478
Amounts owed by group undertakings	839,307	1,245,764
Other debtors	90,159	334,971
	<u>1,204,895</u>	<u>1,585,213</u>

9. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Net obligations under finance lease and hire purchase contracts	9,400	9,400
Trade creditors	370,677	364,436
Bank loans and overdrafts	241,002	245,500
Amounts owed to participating interests	370,800	455,543
Other creditors	284,926	392,342
Taxation and social security	35,215	18,642
	<u>1,312,020</u>	<u>1,485,863</u>

10. Obligations Under Finance Leases and Hire Purchase

	2025	2024
	£	£
The future minimum finance lease payments are as follows:		
Not later than one year	9,400	9,400
Later than one year and not later than five years	2,401	11,763
	<u>11,801</u>	<u>21,163</u>
	<u>11,801</u>	<u>21,163</u>

11. Share Capital

	2025	2024
	£	£
Allotted, Called up and fully paid	<u>100</u>	<u>100</u>

12. Related Party Transactions

The company owes £370,800 (2024: £371,543) to NH Pharm Ltd. Nicky Patel and Hiren Patel are directors of this company.

The company owes £96,900 (2024: £96,900) to Baldev Bange a director and shareholder of this company.

The company is owed £839,307 (2024: £1,245,763) by Graphictrail Ltd, a wholly owned subsidiary.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.